(QURE) uniQure N.V. BCG Matrix Research

Hemgenix has European approval, so uniQure can sell beyond the U.S. and tap the EU’s hemophilia B pool, where the annual incidence is about 1 in 25,000 male births. That multi-region reach helps its Stars profile because it supports leadership in a rare, high-value gene-therapy market.

• EU approval widens the addressable market.
• Multi-region sales can lift peak revenue.
• Rare-disease pricing supports margin upside.

CSL Behring gives uniQure a built-in launch engine for HEMGENIX, which lowers the need for a full in-house sales force and speeds market reach. In 2025, HEMGENIX sales remained driven by CSL’s global commercialization setup, while uniQure keeps high-margin economics through the partnership. That supports a stronger growth profile in the BCG Matrix.

• CSL funds launch execution
• Broader reach, lower uniQure spend
• Supports commercial scale-up

Hemgenix gives uniQure N.V. a clear payer case because it is a one-time gene therapy priced at about $3.5 million in the U.S., with long-term bleed reduction replacing years of factor IX therapy. Once reimbursement and center access are in place, selling costs should stay low versus repeat-dose drugs, which supports margin and cash flow. CSL Behring said Hemgenix generated $136 million in 2024 sales, showing the path is already working.

• One-time treatment, not chronic dosing.
• Strong payer value versus lifetime factor costs.
• Lower incremental commercialization spend over time.
• 2024 Hemgenix sales: $136 million.

uniQure N.V.'s near-term revenue is concentrated in Hemgenix, its only commercial product and the first one-time gene therapy for hemophilia B. The U.S. list price is $3.5 million per patient, so this is a single-asset revenue engine. That fits a Cash Cow pattern because mature, concentrated sales can fund the pipeline.

• Only commercial product: Hemgenix
• U.S. price: $3.5 million
• Revenue is highly concentrated
• Cash generated can support R&D

AMT-060 has no marketed brand and is not sold commercially, so it brings in no product revenue. With zero sales to defend share, it fits the BCG Dog profile: low share, low growth, and no clear cash engine for uniQure N.V.

In uniQure N.V.'s 2025 reporting, the company still had no commercial AMT-060 revenue, so the asset does not support a market position.

• Not commercialized
• No revenue base
• Low share, low growth
• Dog status

uniQure’s disclosed development focus is now centered on its lead programs, so a de-emphasized pipeline slot fits Dog logic: lower strategic priority, weaker capital support, and a harder path to value creation. When management shifts resources away from a program, turnaround odds usually fall fast, especially in gene therapy where each new study update can reset expectations.

• Lower priority means lower funding.
• Less focus hurts turnaround odds.
• Dog status fits weak strategic fit.

AMT-161 is uniQure N.V.’s early-stage gene therapy candidate for amyotrophic lateral sclerosis, so it sits in the Question Marks bucket: high upside, but no commercial traction yet. ALS affects about 5 in 100,000 people, and uniQure’s 2025 filings show the company is still funding a pipeline with no AMT-161 revenue today.

• Early-stage, precommercial asset
• No market share yet
• High upside if data readouts succeed
• Value depends on clinical and regulatory progress

AMT-240 is uniQure N.V.’s earliest-stage asset: a preclinical gene therapy for autosomal dominant Alzheimer’s disease, so it fits the Question Marks bucket in the BCG Matrix. It has high long-term upside, but the program has very high technical and regulatory risk and generates no revenue today.

• Preclinical, earliest pipeline stage
• ADAD target, high unmet need
• No revenue; high uncertainty